Rozlytrek (entrectinib) is a small molecule pharmaceutical. Entrectinib was first approved as Rozlytrek on 2019-08-15. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat neoplasms and non-small-cell lung carcinoma. Rozlytrek's patents are valid until 2038-07-18 (FDA).
|Indication||neoplasms, non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors|